There's good and bad news. The good news is 'Kymriah' has been approved by U.S. regulators as an effective treatment for common childhood cancers. The bad news is… It costs $475,000. How does it work? Kymriah uses a patient's own cells to fight off cancerous cells. Novartis developed the drug and found 85 percent of children went into remission for five years or more. Novartis CEO Joseph Jimenez Are you in the one percent that can afford the drug?